Abstract: The diagnosis of metastatic clear cell renal cell carcinoma (CC-RCC) can be difficult because of its morphologic heterogeneity and the increasing use of small image-guided biopsies that yield scant diagnostic material. This is further complicated by the degree of morphologic and immunophenotypic overlap with nonrenal neoplasms and tissues, such as adrenal cortex. In this study, a detailed immunoprofile of 63 adrenal cortical lesions, which included 54 cortical neoplasms, was compared with 185 metastatic CC-RCCs using traditional [anticalretinin, CD10, antichromogranin, antiepithelial membrane antigen, anti-inhibin, antimelanA, anticytokeratins (AE1/ AE3 and AE1/CAM5.2), antirenal cell carcinoma marker, and antisynaptophysin)] and novel [anticarbonic anhydrase-IX, antihepatocyte nuclear factor-1b, antihuman kidney injury molecule-1 (hKIM-1), anti-PAX-2, anti-PAX-8, antisteroidogenic factor-1 (SF-1), and anti-T-cell immunoglobulin mucin-1] antibodies. Tissue microarray methodology was used to simulate small image-guided biopsies. Staining extent and intensity were scored semiquantitatively for each antibody. In comparing different intensity thresholds required for a "positive" result, a value of Z2+ was identified as optimal for diagnostic sensitivity/specificity. For the distinction of adrenal cortical lesions from metastatic CC-RCCs, immunoreactivity for the adrenal cortical antigens SF-1 (86% adrenal; 0% CC-RCC), calretinin (89% adrenal; 10% CC-RCC), inhibin (86% adrenal; 9% CC-RCC), and melanA (86% adrenal; 10% CC-RCC) and for the renal epithelial antigens hKIM-1 (0% adrenal; 83% CC-RCC), PAX-8 (0% adrenal; 83% CC-RCC), hepatocyte nuclear factor-1b (0% adrenal; 76% CC-RCC), epithelial membrane antigen (0% adrenal; 78% CC-RCC), and carbonic anhydrase-IX (3% adrenal; 87% CC-RCC) had the most potential use. Use of novel renal epithelial markers hKIM-1 (clone AKG7) and/or PAX-8 and the adrenocortical marker SF-1 in an immunohistochemical panel for distinguishing adrenal cortical lesions from metastatic CC-RCC offers improved diagnostic sensitivity and specificity.
C lear cell renal cell carcinoma (CC-RCC) metastasizes frequently and may involve virtually any body site. 14, 37, 48 The increasing use of image-guided biopsies 15, 17, 38, 46 that yield very scant tissue samples often complicates the diagnosis at a metastatic location. In addition, CC-RCC has considerable morphologic overlap with other nonrenal neoplasms and normal tissues, 31, 39 especially primary lesions of the adrenal cortex such as adenoma, carcinoma, hyperplasia, and even adrenal-renal fusion. The histologic distinction of CC-RCC from an adrenal cortical lesion, either at the time of staging or in a patient with a remote history of CC-RCC, poses a wellrecognized diagnostic difficulty 39, 51 that has significant therapeutic and prognostic implications. 18, 26, 32, 43 Although immunohistochemistry can be helpful in difficult cases, we have encountered problems of weak immunoreactivity with both presumed adrenal corticalspecific markers (calretinin, inhibin, and melanA) and presumed CC-RCC-specific markers [CD10, cytokeratins (CK), epithelial membrane antigen (EMA), renal cell carcinoma marker (RCCma)] in cases of metastatic CC-RCC and adrenal cortical lesions, respectively. Clinically, the occurrence of steroid-inactive adrenal cortical lesions may further confound histologic interpretation. 8, 30, 40 Although earlier studies have compared immunostaining results in this setting, [2] [3] [4] [5] [6] [9] [10] [11] [12] 16, 25, 27, 33, 34, 36, 41, 42, 44, 45, 50, 53, 54 our goal was to characterize the immunoprofile of primary lesions of the adrenal cortex and metastatic CC-RCC using tissue microarray technology to simulate the small biopsy samples obtained in routine practice, with a focus on the effect of varying intensity thresholds on sensitivity and specificity. In addition, the immunoprofile of the proposed renal cell carcinoma markers anticarbonic anhydrase IX (CAIX), antihuman kidney injury molecule-1 (hKIM-1), antihepatocyte nuclear factor-1b (HNF-1b), anti-PAX-8, and anti-T-cell immunoglobulin mucin-1 (TIM-1) 7, 13, 21, 22, 29, 47 (which to our knowledge have not been fully characterized in adrenal cortical lesions) was studied to determine diagnostic utility in this setting.
MATERIALS AND METHODS
Sixty-three adrenal cortical lesions and 185 metastatic CC-RCCs were retrieved from the pathology archives of Stanford University Medical Center and Veterans Affairs Palo Alto Health Care System from 1992 to 2008 after Institutional Review Board approval. Only metastatic CC-RCC cases with a documented primary renal cell carcinoma history (by chart review or archival pathology database review) were included in the study. We studied only metastases to avoid the possibility of inflating the sensitivity of the renal markers by using primary renal tumors and to expand knowledge of the immunophenotypic spectrum of metastatic renal cell carcinoma. In some cases with synchronous metastasis in other organs/sites (ie, lung and multiple lymph node metastasis), 1 representative block per unique organ/site was selected. Nineteen primary CC-RCCs (concurrent or earlier) corresponding to a metastatic CC-RCC were also available and retrieved to investigate immunostaining constancy between the metastasis and primary tumor.
All hematoxylin and eosin-stained sections were studied by 2 investigators (A.R.S. and J.K.M.) and diagnoses for all cases were confirmed. Adult adrenal cortical neoplasms were classified by the modified Weiss criteria 1, 20, 49 ; pediatric adrenal cortical neoplasms were classified separately. 52 Before staining, cases of metastatic CC-RCC were classified as well differentiated or poorly differentiated, based on whether morphologic features were suggestive of CC-RCC (well differentiated) or whether the diagnosis of CC-RCC would not have been suspected by morphology alone (poorly differentiated). Relevant clinicopathologic parameters evaluated for all cases included patient age and sex, tumor site, and tumor laterality.
Unique tissue microarrays (TMA) for the 63 adrenal cortical lesions (Stanford TMA #240) and 185 metastatic CC-RCCs (Stanford TMA #238) were prepared in duplicate and evaluated as described elsewhere 19 ,40 using 1.3-mm-diameter and 0.7-mm-diameter tissue cores, respectively. The 19 corresponding primary renal cell carcinomas were included on the metastatic CC-RCC tissue microarray. Incomplete or missing cores were excluded from evaluation. Immunohistochemical staining using antibodies against calretinin, CAIX, CD10, CKAE1/AE3, CKAE1/CAM5.2, EMA, inhibin, hKIM-1, HNF-1b, melanA, PAX-2, PAX-8, RCCma, SF-1, synaptophysin, and TIM-1 was performed on 4-mmthick formalin-fixed, paraffin-embedded duplicate sections mounted on charged slides and baked at 601C for 1 hour. As immunoreactivity for calretinin, inhibin, melanA, SF-1, and synaptophysin in adrenal cortical lesions had been previously performed and reported by our group, 40 these markers were not repeated for this study. Antibody sources and dilutions for the study are listed in Table 1 .
Whole sections of CC-RCC were used as a positive control for the antibodies against CAIX, CD10, CKAE1/ AE3, CKAE1/CAM5.2, EMA, hKIM-1, HNF-1b, PAX-2, wAll stains were performed on the Ventana Benchmark, except synaptophysin, h-KIM1, HNF-1b, and TIM-1. Synaptophysin was run on the Dako Autostainer using the Envision+ detection system and hKIM-1, HNF-1b, and TIM-1 were performed manually.
PAX-8, RCCma, and TIM-1, whereas whole sections of normal adrenal gland were used as positive control for the antibodies against calretinin, inhibin, melanA, SF-1, and synaptophysin. The following patterns of immunostaining were considered positiveF anti-HNF-1b, anti-PAX-2, anti-PAX-8, anti-SF-1: nuclear; anticalretinin: nuclear and cytoplasmic; antiinhibin, antimelanA, antisynaptophysin: cytoplasmic; anti-CAIX, anti-CKAE1/ AE3, anti-CKAE1/CAM5.2, CD10, anti-EMA, antihKIM-1, anti-RCCma, anti-TIM-1: membranous and/or cytoplasmic. Staining extent was semiquantitatively scored as negative (0,<5% cells stained), focally positive (1+, 5% to 10% cells stained), positive (2+,>10% to 50% cells stained), or diffusely positive (3+,>50% cells stained), and a mean extent (range, 0 to 3) was calculated. Staining intensity was semiquantitatively scored from 0 to 3+ and a mean intensity (range, 0 to 3) was calculated.
RESULTS

Clinical Features: Adrenal Cortical Lesions Versus Metastatic CC-RCC
On the TMA, 63 adrenal cortical lesions were intact/complete and available for evaluation. The adrenal cortical lesions consisted of cortical adenomas (43) , cortical neoplasms of uncertain malignant potential (4), cortical carcinomas (7), cortical hyperplasias (6), and cortical rests (3). For adrenal cortical lesions, the patient age ranged from 1 to 86 years (mean, 48.7 y) and the size of lesions ranged from 0.3 to 18 cm (mean, 4.2 cm). Thirty-one patients were male and 32 were female; 35 were left sided and 28 were right sided.
One hundred eight-five metastatic CC-RCCs were intact/complete and available for evaluation on the TMA. In all, 133 were well differentiated and 52 were poorly differentiated, as defined for this study. For some antibody tests, one of the represented tumors may have not been evaluable; therefore, a sample size of 184 cases is reported in some staining results. Metastatic CC-RCC was identified in 27 unique sites: bone (21%), lung (21%), lymph node (16%), soft tissue (9%), brain (6%), blood vessel (4%), skin (3%), adrenal (3%), parotid (3%), pleura (2%), sinonasal (2%), and 16 other miscellaneous sites (10% combined). The patient age ranged from 34 to 85 years (mean, 60.8 y). One hundred fifty-four patients were male and 31 were female.
Immunohistochemical Results: Adrenal Cortical Lesions Versus Metastatic CC-RCC
Previously reported studies comparing immunohistochemical staining in adrenal cortical lesions and CC-RCC were reviewed and are summarized in Figure 1 . Our staining results are summarized in Tables 2 and 3 .
Anti-CAIX showed the highest overall sensitivity for CC-RCC using Z2+ staining intensity as the threshold for a positive result (87%), but it was slightly less sensitive in poorly differentiated tumors (80%) compared with hKIM-1 (83%) and PAX-8 (86%). AntihKIM-1 and anti-PAX-8 also showed slightly better overall specificity for CC-RCC versus adrenal cortical lesions compared with anti-CAIX (100% for both antihKIM-1 and anti-PAX-8), as 2 of 63 (3%) adrenal cortical lesions stained for CAIX (1 adrenal cortical adenoma and 1 carcinoma). The other potential renal markers in this differential diagnostic setting had lower sensitivities: anti-PAX-2 (49%), anti-CKAE1/CAM5.2 (60%), anti-CKAE1/AE3 (55%), CD10 (77%), anti-EMA (78%), anti-HNF-1b (76%), anti-RCCma (18%), and anti-TIM-1 (37%).
Photomicrographs depicting the prototypical immunophenotypes of adrenal cortex and CC-RCC are shown in Figure 2 . Figure 3 shows the intensity threshold definitions used for immunohistochemical interpretation in the study (ie, 1+ and Z2+). Sensitivities and specificities for both adrenal cortical lesions and metastatic CC-CC, including a comparison of different results by staining intensity thresholds, are shown in Figures 4  and 5 .
Among the presumed adrenal cortex-specific markers, anticalretinin showed a slightly higher sensitivity for adrenal cortical lesions than anti-SF-1 (89% vs. 86%, respectively); however, it lacked the high specificity of anti-SF-1 (100%), as anticalretinin also stained 10% of metastatic CC-RCCs using a Z2+ positivity cut point. Anti-SF-1 maintained strong consistency in staining intensity, with 54 of 55 (98%) positive adrenal cortical lesion cases showing Z2+ staining intensity. Both anti-inhibin and antimelanA showed an identical sensitivity to anti-SF-1 (86%), but with lower specificities (90% and 91%, respectively, compared with 100% for SF-1). Although antisynatophysin reactivity was relatively specific for adrenal cortical lesions (98% using a Z2+ positivity cut point), sensitivity was much lower than for other markers tested (59% using a Z2+ positivity cut point). No significant difference in staining was seen among the subtypes of adrenal cortical lesions evaluated.
Immunohistochemical Results: Primary Versus Metastatic CC-RCC
For the 19 metastatic CC-RCCs with available paired primary CC-RCCs, immunoreactivity for all proposed renal epithelial markers studied was compared between the primary and metastatic carcinomas. AntihKIM-1 had the highest sensitivity among primary CC-RCC markers (100%), while also showing strong constancy with metastatic CC-RCC (95%), including the poorly differentiated metastatic carcinomas (80%). Although anti-CKAE1/AE3 showed the highest constancy between primary and metastatic tumors (100%), it had the lowest sensitivity among primary CC-RCC markers (37%).
DISCUSSION
Given the common use of image-guided biopsies for the diagnosis of deep-seated mass lesions, 15, 17, 38, 46 the amount of tissue available for pathologic evaluation has become increasingly smaller. As some of the morphologic clues to diagnosis, such as architectural growth pattern, are not evaluable in many of these small samples, immunohistochemistry is often required to determine tissue type or tumor lineage. Adjunctive studies are even more commonly needed when considering a diagnosis of metastatic CC-RCC because of its overlapping morphologic appearance with a variety of other tissues and neoplasms. Distinction of CC-RCC from adrenal cortical tissue, whether normal, hyperplastic, or neoplastic, can be a major diagnostic problem. Anecdotally, we have seen a few cases of adrenal-renal fusion initially interpreted as CC-RCC on biopsy. Although there are many previous studies of immunohistochemical markers used for the diagnosis of RCC, [2] [3] [4] [5] [6] [9] [10] [11] [12] 16, 25, 27, 33, 34, 36, 41, 42, 44, 45, 50, 53, 54 it is our experience that overlapping immunophenotypes are more commonly seen in routine practice than would be expected from the reported literature. In addition, the appropriate diagnostic threshold for regarding a stain as "positive" has not been fully addressed in this setting. We sought to address several of these unresolved issues: threshold requirements (ie, minimal staining intensity) for accurate diagnosis, comparative expression within the spectrum of primary adrenal cortical mass lesions and metastatic CC-RCC, comparison of sensitivities in both well-differentiated and poorly differentiated metastatic CC-RCC, and an evaluation of novel markers that have not been fully tested in this setting. All of these issues were addressed using tissue microarray methodology to simulate small biopsy samples.
In the differential diagnostic setting of CC-RCC versus adrenal cortical lesions, this current comparison of traditional and novel renal-specific antibodies showed that anti-hKIM-1 (clone AKG7), anti-PAX-8, and anti-CAIX were the superior markers in terms of sensitivity for metastatic CC-RCC using either the Z1+ or Z2+ positivity cut point. Setting a higher threshold (Z2+) was more important for the traditional CC-RCC markers, which had more frequent weak staining in adrenal tissues (using Z2+ cut point; Fig. 5 ). Both anti-hKIM-1 and anti-PAX-8 also show the highest consistency in staining intensity across well-differentiated and poorly differentiated metastatic CC-RCCs. This maintained sensitivity in poorly differentiated CC-RCCs is important because the sensitivity of many tissue-specific antibodies markedly declines with increasing tumor grade. The antibodies antihKIM-1, anti-PAX-8, and anti-CAIX also show excellent staining constancy between primary and concurrent/corresponding metastatic CC-RCCs. Although HNF-1b results were very promising, we have had trouble obtaining adequate staining with the subsequently purchased antibody of a different lot number.
Although one would expect similar immunoreactivity for PAX-2 and PAX-8, given their shared role as transcription factors in renal organogenesis and the fact that PAX-8 is always coexpressed with PAX-2 in embryonal and renal tissues, 35, 47 PAX-8 had a much higher sensitivity for metastatic CC-RCC and also higher staining constancy between primary and metastatic CCRCCs. Although lowering the dilution used for PAX-2 increases sensitivity to a level comparable to PAX-8, we have previously shown that this reduces specificity for metastatic CC-RCC compared with adrenal cortical lesions (43% vs. 100% for 1:50 and 1:100 PAX-2 dilution, Adrenal Cortical Lesions Versus Metastatic RCC respectively). 28 Over the past several years, we have anecdotally noted a decreasing sensitivity of the anti-PAX-2 antibody for CC-RCC in our daily clinical practice, compared with the results that we observed in our previous studies. 12 The diagnostic specificity of anticalretinin, antiinhibin, and antimelanA for adrenal cortical lesions in a small biopsy sample can be particularly problematic if the Z2+ staining requirement is not maintained, similar to the findings we reported for discrimination from pheochromocytoma. 40 Patchy cytoplasmic staining with anticalretinin, antiinhibin, and antimelanA was seen in 28%, 15%, and 20% of metastatic CC-RCCs, respectively (Figs. 3, 4 ). The addition of nuclear marker anti-SF-1 to a diagnostic panel offers improved specificity for adrenal cortical lesions (100%) and may also counter the issues of nonspecific cytoplasmic staining.
Although previous immunohistochemical studies have incorporated staining for the antigens S-100 protein and vimentin in the differential diagnosis of adrenal cortical lesions versus CC-RCC (along with other markers), 6, 10, 33, 50 these markers were excluded from this study given the known overlap in immunoreactivity (Fig. 1) . In addition, 1 study has reported 100% specificity of the antibody D2-40 (antipodoplanin) for adrenal cortical lesions, 3 but we were unable to achieve satisfactory staining and it was therefore excluded from further evaluation.
hKIM-1 is a biomarker for renal proximal tubules undergoing regeneration from tubular injury and has been recently recognized as a sensitive immunohistochemical marker of CC-RCC. 13, 22 The specificity of this antibody in nonrenal tumors has only been explored in a few previous studies, and reactivity has been reported in 1 of 2 hepatocellular carcinomas, 13 22 and 16% (10 of 64) of papillary urothelial carcinomas. 23 At present, the anti-hKIM-1 clone AKG7 is not commercially available, but commercial antibodies are under development. We did test a commercial antibody (anti-TIM-1, clone 219211) that should share significant homology with the anti-hKIM-1 (AKG7) antibody; however, it had a very low sensitivity in this study that would preclude its routine use in the diagnosis of CC-RCC.
In summary, we show that incorporating the novel renal epithelial markers anti-hKIM-1 (as it becomes commercially available) and/or anti-PAX-8, and the adrenocortical marker anti-SF-1 in an immunohistochemical panel for the diagnostic distinction of metastatic CC-RCC from adrenal cortical lesions offers improved diagnostic sensitivity and specificity over traditional markers used in this differential diagnostic setting. 
